Navigation Links


BioCryst in Medical News

BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update

...IRMINGHAM, Ala., July 30 /PRNewswire-FirstCall/ -- biocryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today anno...i.v.) peramivir in the U.S. "Our efforts at biocryst remain focused on moving our leading peramivir and...onehouse, President and Chief Executive Officer of biocryst Pharmaceuticals. "BioCryst continues to work dili...

BioCryst Pharmaceuticals Announces Presentation of Forodesine Data at the 45th Annual Meeting of the American Society of Clinical Oncology

...RMINGHAM, Ala., May 14 /PRNewswire-FirstCall/ -- biocryst Pharmaceuticals (Nasdaq: BCRX ) today announced ... of the nine subjects, respectively. About biocryst biocryst is a biopharmaceutical company that has developed ...

BioCryst to Present at the 11th Annual BIO CEO & Investor Conference

...RMINGHAM, Ala., Feb. 2 /PRNewswire-FirstCall/ -- biocryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today anno...eb cast of the presentation may be accessed on the biocryst Web site at http://www.biocryst.com . The presentation will be archived for 14 days. About biocryst ...

BioCryst Pharmaceuticals to Announce Fourth Quarter and Year End 2008 Financial Results on February 6, 2009

...IRMINGHAM, Ala., Jan. 30 /PRNewswire-FirstCall/ -- biocryst Pharmaceuticals (Nasdaq: BCRX ) today announced ...n Friday, February 6, 2009. Following the release, biocryst will host a conference call and Web cast at 8:30 a... and available for replay for 14 days. About biocryst ...

BioCryst to Present at the Rodman and Renshaw 10th Annual Healthcare Conference

...eb cast of the presentation may be accessed on the biocryst Web site at http://www.biocryst.com . The present...ll be archived for ninety days. About BioCryst biocryst is an integrated biopharmaceutical company utilizi...e of novel therapeutics targeting major illnesses. biocryst is currently advancing investigational new drugs d...

BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza

...ionogi & Co., Ltd. Partnership In February 2007, biocryst and Shionogi & Co., Ltd. entered into an exclusive...s rights were extended to include Taiwan. In 2007, biocryst received a $14 million up-front payment and may al...e) royalty payments on product sales of peramivir. biocryst retains all rights to commercialize peramivir in N...

BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008

...n Thursday, May 8, 2008. At 8:30 a.m. Eastern Time biocryst will host a conference call and webcast to discuss...ailable for replay for 14 days. About BioCryst biocryst Pharmaceuticals, Inc. is a leader in the use of cr...amivir in seasonal and life-threatening influenza. biocryst has a worldwide partnership with Roche for the dev...

BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007

...day, November 8, 2007. At 10:00 a.m. Eastern Time, biocryst will host a conference call and live webcast. The ...Senior Vice President and Chief Financial Officer. biocryst management will discuss the Company's third quarte... be archived on https://www.biocryst.com . About biocryst ...

BioCryst Receives Special Protocol Assessment for Fodosine

... biocryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announc...guidance on the design of pivotal trial protocols. biocryst requested the formal assessment, late in the first... their input and guidance during this SPA process. biocryst is now well positioned to begin patient enrollment...

BioCryst’s Bird Flu Drug Enjoys Fast-Track Review By FD

...stration. // This novel drug, produced by the pharmaceutical company biocryst can be injected intravenously. Promising results have been obtained from dr... life-threatening strains like those associated with avian influenza," said biocryst Chairman and CEO Charles Bugg. The FDA had approved the launch of h...
BioCryst in Medical Technology

BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza

...MINGHAM, Ala., July 17 /PRNewswire-FirstCall/ -- biocryst Pharmaceuticals (Nasdaq: BCRX ) today announced ...ral treatment options for influenza remains high. biocryst is currently finalizing its plans for peramivir Ph... "This data represents a significant milestone for biocryst -- the first Phase 3 studies successfully conducte...

BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results

... BIRMINGHAM, Ala., May 8 /PRNewswire-FirstCall/ -- biocryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today anno...uenza outbreak with significant hospitalizations. biocryst is advancing the clinical development of peramivir...ral or inhaled anti-viral medication. In addition, biocryst is in negotiations with the Division of Microbiolo...

BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009

... BIRMINGHAM, Ala., May 7 /PRNewswire-FirstCall/ -- biocryst Pharmaceuticals (Nasdaq: BCRX ) today announced ...ed on Friday, May 8, 2009. Following the release, biocryst will host a conference call and Web cast at 8:30 a... available for replay for 14 days. About biocryst ...

Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections

...IRMINGHAM, Ala., Feb. 23 /PRNewswire-FirstCall/ -- biocryst Pharmaceuticals (Nasdaq: BCRX ) today announced ...vir in outpatient influenza underway. About biocryst biocryst is an integrated biopharmaceutical company utilizi...

BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting

...ddressing seasonal influenza." In February 2007, biocryst and Shionogi entered into an exclusive license agr...e) royalty payments on product sales of peramivir. biocryst retains all rights to commercialize peramivir in N... outside of Japan and Korea. Earlier this month, biocryst commenced a Phase II study of intra-muscular (i.m....

BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza

...tment of influenza infections." About BioCryst biocryst Pharmaceuticals, Inc. is a leader in the use of cr...amivir in seasonal and life-threatening influenza. biocryst is collaborating with Mundipharma for the developm...S) awarded a $102.6 million, four-year contract to biocryst to advance development of peramivir to treat seaso...

BioCryst Updates Peramivir Clinical Development Plan

...er dose of peramivir later this year. As a result, biocryst will not continue to pursue a pivotal Phase III pr... a successful result." After discussions between biocryst and HHS, the Company believes that peramivir remai...tially important therapy available to patients." biocryst will sponsor a conference call at 8:00 am Eastern ...

Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma

...tion previously presented at the 2006 ASH meeting. biocryst is currently enrolling subjects in a pivotal trial...tions in the treatment of CLL." About BioCryst biocryst Pharmaceuticals, Inc. is a leader in the use of cr...mivir in seasonal and life- threatening influenza. biocryst has a worldwide partnership with Roche for the dev...

BioCryst Provides Forodesine HCl Update

...t information presented at the 2006 ASH meeting. biocryst to Voluntarily Discontinue Clinical Study of Intra... After review and consultation with Mundipharma, biocryst has decided to voluntarily and formally discontinu...cal trial for this indication. On March 27, 2007 biocryst announced that as the result of a stability issue,...

BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)

...en the U.S. Food and Drug Administration (FDA) and biocryst which was granted earlier this year. The study wil...L), and chronic lymphocytic leukemia (CLL). About biocryst biocryst Pharmaceuticals, Inc. is a leader in the use of cr...
BioCryst in Biological Technology

William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals

BIRMINGHAM, Ala., June 18 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX ) today announced that William P. Sheridan, MB BS, has been appointed Chief Medical Officer of BioCryst, effective July 1, 2008. Dr. Sheridan is a seasoned biotechnology professional, most recently serv...

BioCryst Pharmaceuticals to Announce Second Quarter 2009 Financial Results on July 30, 2009

...IRMINGHAM, Ala., July 28 /PRNewswire-FirstCall/ -- biocryst Pharmaceuticals (Nasdaq: BCRX ) today announced ...ults will be released on Thursday, July 30, 2009. biocryst will host a conference call and Web cast at 11:00 ...le for replay for at least 14 days. About biocryst ...

Novavax Appoints Stanley Erck to Board of Directors

...e his anticipated contributions to our future success as we expand our pipeline of promising vaccine candidates." Mr. Erck is also a Director of biocryst Pharmaceuticals, MaxCyte, Inc. and MdBio Foundation. He received his undergraduate degree from the University of Illinois and his masters in busine...

Techne Corporation Announces That John L. Higgins has Accepted a Seat on Techne's Board

...ously a member of the executive management team at biocryst Pharmaceuticals, Inc., a biopharmaceutical company. Currently, he is a Director of biocryst and serves as Chairperson of its Audit Committee. Before joining biocryst in 1994, Mr. Higgins was a member of the healthcar...

Biotech Drops on Weaker First Quarter Drug Sales, But Broader Markets Remain on a Roll

...rds, and humans. "Apart from those biotech companies that are linked to combating a potential flu pandemic, such as Gilead Sciences, Novavax and biocryst Pharmaceuticals, biotech didn't fare as well as the general markets," said G. Steven Burrill, CEO, Burrill & Company, a San Francisco based global...

Antiviral Drugmaker Shares Soar as Swine Flu Spreads; Beacon Equity Issues Stock Alerts on: HEB, GNBT, BCRX, DVAX, NVAX, SVA

... stockhideout.com . Today's Stock Alerts include: Hemispherx Biopharma Inc. (AMEX: HEB ), Generex Biotechnology Corp. (Nasdaq: GNBT ), biocryst Pharmaceuticals Inc. (Nasdaq: BCRX ), Dynavax Technologies Corp. (Nasdaq: DVAX ), Novavax Inc. (Nasdaq: NVAX ) and Sinovac Biotech Ltd. (AMEX: ...

BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update

...BIRMINGHAM, Ala., Feb. 6 /PRNewswire-FirstCall/ -- biocryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today anno...hich is in-line with the Company's 2008 guidance. biocryst expects the Company's net cash use in 2009 will be... compared to placebo. biocryst will present results from the previously announced...

BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference

...BIRMINGHAM, Ala., Jan. 8 /PRNewswire-FirstCall/ -- biocryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today anno...eb cast of the presentation may be accessed on the biocryst Web site at www.biocryst.com . The presentation will be archived for ninety days. About biocryst ...

BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition

...BIRMINGHAM, Ala., Dec. 5 /PRNewswire-FirstCall/ -- biocryst Pharmaceuticals (Nasdaq: BCRX ) announced today ...:00 p.m. Pacific Time; Hall A About biocryst biocryst is an integrated biopharmaceutical company utilizi...

BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update

...ith i.v. peramivir in the outpatient setting. -- biocryst reported results of an exploratory Phase 2 trial o... be submitted to an upcoming medical meeting. -- biocryst reported top-line results from the completed Phase...download that may be necessary. About BioCryst biocryst is an integrated biopharmaceutical company utilizi...
Other TagsWHIWHIWHIWHIWHIWHI
(Date:11/30/2009)...O A large proportion of patients who undergo abdo...dicated and unnecessary additional image acquisiti...re, according to a study presented today at the an...America (RSNA). , "It is the responsibility of a...ensure that the dosage is as low as reasonably ach...
(Date:11/29/2009)..., ATLANTA, Nov. 29 The followin...livest Securities Research, Inc. ,, Intellivest...stered investment advisor, has published a Report ... in the pharmaceutical, biotechnology and medical ...heir clients manage, process and submit medical im...
(Date:11/29/2009)...ng someone get blamed for something leads to more ... , SUNDAY, Nov. 29 (HealthDay News) -- The bl... even when the target is innocent. , Researcher... else for a problem, even if it,s an unfair accusa...g others, too. , "When we see others protectin...
(Date:11/28/2009)... , CHICAGO, Nov. 28 Welcome to...solution for the clinical routine from Siemens H...Communications System (PACS) from Siemens where ... syngo .plaza is poised to change the way mul...ling this innovation at the 95th Scientific Asse...
(Date:11/27/2009)..., BEDFORD, Mass., Nov. 27 /PRNewswire-FirstCall...any"), a supplier of precision technology products...n annual meeting of the Company,s shareholders has...ime and location of the meeting will be announced ...ny received a requisition notice from Stephen Bers...
Breaking Medicine News(10 mins):Health News:Unindicated CT series result in unnecessary radiation exposure for patients 2Health News:Unindicated CT series result in unnecessary radiation exposure for patients 3Health News:Research Report on BioClinica, Inc. as Speculative Buy 2Health News:When Accusations Start to Fly, They Multiply 2Health News:Siemens Healthcare Unveils syngo.plaza at RSNA 2009 2Health News:Siemens Healthcare Unveils syngo.plaza at RSNA 2009 3Health News:GSI Group Calls Shareholders Meeting 2
(Date:11/26/2009)...ve at last worked out a way of using recordings of...opulations. This is the first time sound recording...o accurate estimates of bird species, populations....h Ecological Society,s Journal of Applied Ecology...o a major advance in our ability to monitor whale ...
(Date:11/25/2009)...if.Scientists at the California Institute of Techn...tive emotion-like behavior in the fruit fly, Dros...y be relevant to the relationship between the neur...ctivity disorder (ADHD), are described in the Dece...phila brain contains only about 20,000 neurons an...
(Date:11/25/2009)...NOVEMBER 25, 2009 Soil is the linchpin of the env...here meet. Despite that, many students see soil as...more. Soil science educators are challenged with t...ze the critical importance of soil in the environm...and earth science teachers at University of Nebras...
Breaking Biology News(10 mins):Ecologists sound out new solution for monitoring cryptic species 2Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 2Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 3Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 4It's not just dirt! 2Waste in the U S Healthcare System Pegged at 24700 Billion in Report From Thomson Reuters 60058 1Waste in the U S Healthcare System Pegged at 24700 Billion in Report From Thomson Reuters 60058 2AlterGs Revolutionary Anti Gravity Treadmill 28R 29 Reaches a Wider Audience With the New M300 Series 60055 1AlterGs Revolutionary Anti Gravity Treadmill 28R 29 Reaches a Wider Audience With the New M300 Series 60055 2AlterGs Revolutionary Anti Gravity Treadmill 28R 29 Reaches a Wider Audience With the New M300 Series 60055 3AlterGs Revolutionary Anti Gravity Treadmill 28R 29 Reaches a Wider Audience With the New M300 Series 60055 4STAAR Surgical Collamer 28R 29 Accommodating Study Team Reports First Phase Assessments at AAO 60052 1STAAR Surgical Collamer 28R 29 Accommodating Study Team Reports First Phase Assessments at AAO 60052 2STAAR Surgical Collamer 28R 29 Accommodating Study Team Reports First Phase Assessments at AAO 60052 3STAAR Surgical Collamer 28R 29 Accommodating Study Team Reports First Phase Assessments at AAO 60052 4STAAR Surgical Collamer 28R 29 Accommodating Study Team Reports First Phase Assessments at AAO 60052 5STAAR Surgical Collamer 28R 29 Accommodating Study Team Reports First Phase Assessments at AAO 60052 6
Other Contentsexpectorantemergenciesemergenciesburningburningburningburningextremityextremityextremityextremityexudatefaceliftconditionsconditionsconditionsconditionsconditionsconditionsconditionsconditionsconditionsconditionsmovementsmovementsmovementsmovementsmovementsmovementsmovementsmovements